钆对比剂在识别胰腺囊性病变恶性潜能中的效用
本研究以细胞病理学为参考标准,回顾性纳入2015年1月1日至2019年1月1日期间87例无症状胰腺囊性病变患者,由两名腹部放射科医师分别评估不含对比剂序列与包含增强序列的MRI,比较观察者间与观察者内一致性及诊断准确性。结果显示,增强与否对判断病变良恶性的诊断准确性无显著影响,两名阅片者的一致性相似。
要点
- 两名阅片者在不含与包含增强序列的MRI上判断任何可疑特征/高危征象的一致性均很高(阅片者1 k=0.874,阅片者2 k=0.920)。
- 以任何可疑特征/高危征象预测恶性时,不含与包含增强序列的AUC在阅片者1均为0.622(p=1.0),阅片者2分别为0.569与0.589(p=0.08),差异无统计学显著。
- 加入钆对比剂对判断胰腺囊性病变良恶性无显著影响,增强与不增强MRI数据集的一致性和诊断准确性相似。
核心结论
- 加入钆对比剂对胰腺囊性病变良恶性的诊断无显著影响,两名阅片者使用增强与不增强MRI数据集时观察者内一致性和诊断准确性相似。
研究设计与样本
- 回顾性研究,检索机构数据库纳入2015年1月1日至2019年1月1日期间接受EUS/FNA或手术切除的无症状胰腺囊性病变连续患者87例(87个囊肿),以细胞病理学为参考标准。
诊断标准与关键数值
- 87个囊肿中良性76个(87.4%),恶性11个(12.7%)。
- 阅片者1对任何可疑特征/高危征象的判断在两种MRI上一致率为95.4%(83/87;k=0.874)。
- 阅片者2对任何可疑特征/高危征象的判断在两种MRI上一致率为96.6%(84/87;k=0.920)。
- 以任何可疑特征/高危征象预测恶性时,阅片者1在不含与包含增强序列MRI的AUC均为0.622(p=1.0)。
- 以任何可疑特征/高危征象预测恶性时,阅片者2在不含与包含增强序列MRI的AUC分别为0.569与0.589(p=0.08)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine if gadolinium is necessary for the diagnosis of a pancreatic cystic lesion (PCL) as benign or malignant by assessing inter- and intra-observer agreement and diagnostic accuracy for the presence of worrisome features/high-risk stigmata on non-contrast MRI compared to MRI with and without contrast, with cytopathology as a reference standard.
METHODS: The institutional database was searched to identify consecutive patients that underwent EUS/FNA or surgical resection of an asymptomatic PCL performed from 01/01/2015 to 01/01/2019. Two abdominal radiologists independently evaluated PCLs on MRI with all sequences except for contrast-enhanced sequences followed by a second reading with data from the entire MRI including pre- and post-contrast sequences. Cyst size, growth, and the presence of worrisome features/high-risk stigmata were assessed for each cyst on both datasets.
RESULTS: There were 87 patients with 87 pancreatic cysts; 76(87.4%) were benign and 11 (12.7%) were malignant. The presence of any worrisome features/high-risk stigmata for reader 1 was concordant on both MRIs in 95.4% (83/87; k = 0.874) of cases and for reader 2 was concordant in 96.6% (84/87; k = 0.920) of cases. The diagnostic accuracy of the two datasets when the presence of any worrisome feature/high-risk stigmata was predictive of malignancy was identical for reader 1 (AUC = 0.622 for both; p = 1.0) and similar for reader 2 (AUC 0.569 and 0.589; p = 0.08) for both MRI datasets.
CONCLUSION: The addition of gadolinium had no significant impact in the diagnosis of a benign versus malignant PCL, with similar intra-observer agreement and diagnostic accuracy for both readers when using contrast-enhanced and unenhanced MRI datasets.
引用
- Kierans, Gavlin, Wehrli, et al. Utility of gadolinium for identifying the malignant potential of pancreatic cystic lesions. Abdom Radiol (NY). 2022. PMID: 35195765. doi:10.1007/s00261-022-03446-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。